{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T08:08:24Z","timestamp":1648973304878},"reference-count":3,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,2]],"date-time":"2015-12-02T00:00:00Z","timestamp":1449014400000},"content-version":"vor","delay-in-days":975,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1097\/jto.0b013e318284378f","type":"journal-article","created":{"date-parts":[[2013,3,22]],"date-time":"2013-03-22T21:35:56Z","timestamp":1363988156000},"page":"511-512","source":"Crossref","is-referenced-by-count":1,"title":["\u201cPseudocavitation\u201d in Thymic Carcinoma During Treatment with Sunitinib"],"prefix":"10.1016","volume":"8","author":[{"given":"Marcello","family":"Tiseo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arun","family":"Rajan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anish","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Giaccone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1097\/JTO.0b013e318284378f_bib1","unstructured":"A Phase 2 Study of Sunitinib in Patients with Advanced Relapsed or Refractory Thymoma or Thymic Carcinoma with at Least One Prior Line of Platinum-Based Systemic Chemotherapy. NCT01621568. www.clinicaltrials.gov"},{"key":"10.1097\/JTO.0b013e318284378f_bib2","unstructured":"A Phase 1\/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies. NCT01100944. www.clinicaltrials.gov"},{"key":"10.1097\/JTO.0b013e318284378f_bib3","unstructured":"Pilot Trial of Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies. NCT01306045. www.clinicaltrials.gov"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415327970?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415327970?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,17]],"date-time":"2018-10-17T20:20:56Z","timestamp":1539807656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086415327970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":3,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S1556086415327970"],"URL":"https:\/\/doi.org\/10.1097\/jto.0b013e318284378f","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]}}}